GBP4

Across TCGA pan-cancer cohorts, GBP4 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated GBP4 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher GBP4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GBP4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CHOL, BLCA, and HNSC are the cancer types where GBP4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
BLCA	OS	Median	IV	0.074	0.599	<.001	15	view →
HNSC	DFS	Median	II,III,IV	0.148	0.695	.008	15	view →
LIHC	OS	Median	All	0.255	0.773	.012	9	view →
PRAD	DFS	Median	All	0.788	0.934	.005	6	view →
LUAD	DFS	Median	III,IV	0.059	0.686	<.001	6	view →
GBM	OS	Median	All	0.121	0.415	.042	3	view →
UCEC	DFS	Median	All	0.953	0.628	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

GBP4–CHOL (OS)

Open the CHOL breakdown →